Buccheri G, Ferrigno D
Division of Pneumology, A. Carle Hospital of Chest Diseases, Cuneo, Italy.
Chest. 1992 May;101(5):1287-92. doi: 10.1378/chest.101.5.1287.
The prognostic impact of TPA was evaluated by assaying the marker in the serum of 563 patients with a newly diagnosed bronchogenic carcinoma. The group included patients with squamous cell cancers and others with tumors of diverse or undefined histologies. Raised levels of TPA were clearly associated with a shortened survival, even adjusting for the stage of disease. A Cox's proportional hazards regression analysis, incorporating all major prognostic factors, selected TPA as an independent survival predictor. In the regression model, however, TPA was less important than disease extent, KPS and weight loss. Another multivariate analysis was made in a subgroup of 121 patients who, because of poor KPS or advanced age, had undergone a limited staging workup; TPA came out as the first most important factor. This study shows that TPA is an important prognostic factor and that it should be included among laboratory data evaluated in lung cancer studies.
通过检测563例新诊断为支气管源性癌患者血清中的该标志物，评估组织多肽抗原（TPA）的预后影响。该组包括鳞状细胞癌患者以及其他组织学类型多样或不明确的肿瘤患者。即使对疾病分期进行调整，TPA水平升高也明显与生存期缩短相关。一项纳入所有主要预后因素的Cox比例风险回归分析将TPA选为独立的生存预测指标。然而，在回归模型中，TPA的重要性低于疾病范围、卡氏功能状态评分（KPS）和体重减轻。对121例因KPS差或年龄较大而进行有限分期检查的患者亚组进行了另一项多变量分析；TPA成为最重要的首要因素。这项研究表明，TPA是一个重要的预后因素，应纳入肺癌研究中评估的实验室数据之中。
